Lynx.MD is proud to have supported our partners, Sanofi and Regeneron, in the successful presentation of a new study at the American Rhinologic Society (ARS) 70th Annual Meeting in September 2024. The study provided valuable insights into the characteristics of chronic rhinosinusitis with nasal polyps (CRSwNP) patients in the US healthcare system. The research was conducted using the Lynx.MD platform and real-world data from prominent otolaryngology practices, analyzing patient demographics, clinical features, and treatment patterns.

Poster Session Summary: The poster, titled “A Descriptive Analysis of Characteristics of CRSwNP Patients within US Clinical Practice,” was presented during the ARS 2024 Symposium at the Fontainebleau Miami Beach on September 27-28, 2024. It detailed the outcomes of a retrospective longitudinal study aimed at understanding the real-world characteristics of CRSwNP patients, particularly whether they underwent surgery after diagnosis.

Key Study Findings: The study analyzed data from 6,219 CRSwNP patients diagnosed between July 2018 and December 2022. Researchers categorized patients into surgical and non-surgical groups, finding that:

• 28% (1,726 patients) underwent surgery.
• Surgical patients were younger, with an average age of 47.4 years, compared to the non-surgical group, whose average age was 51.5 years.
• Those who underwent surgery had a higher prevalence of comorbidities such as atopy, allergic rhinitis, and asthma.
• Surgical patients showed greater use of biologic medications (15.5% vs. 11.7%) and began these treatments earlier (426.7 days vs. 498.5 days).
• Oral corticosteroid use was significantly higher among surgical patients (82.9% vs. 57.5%).

Conclusion: The study highlighted distinct differences between surgical and non-surgical CRSwNP patients in the US, with surgical patients tending to be younger and having more complex clinical profiles. This underscores the importance of personalized treatment approaches in managing CRSwNP.

Looking Forward: Lynx.MD is proud to have contributed to this important research by providing access to real-world data and facilitating meaningful insights that can drive better patient outcomes. The results shared at ARS 2024 mark a significant step forward in understanding CRSwNP patient profiles and treatment patterns in the US.